Skip to main content

Biosyent Inc(RX-X)
TSX Venture

Today's Change
Delayed Last Update

Closing Bell: Biosyent Inc flat on Friday (RX)

Automated Summaries - The Globe and Mail - Fri Apr 26, 4:02PM CDT

Today, shares of Biosyent Inc opened at $8.51 and closed at $8.51. prices ranged from a low of $8.45 to a high of $8.69.

Share prices $verbed percentage_change percent from the previous day's close of $8.51.

Today across North America, the TSX Composite closed 0.38% at 21969.24, the S&P 500 closed -0.46% at 5048.42, the Dow Jones Industrial Average closed -0.98% at 38085.80 and the Nasdaq Composite closed -0.64% at 15611.76.

Biosyent Inc has listed on the Toronto Venture Exchange (TSX-V) under the ticker RX.

A total of 3,825 shares was traded during the last trading day, with total trades of 12. On average, Biosyent Inc has traded 16,535 shares in the last five days and 5,930 year-to-date.

Trading across the entire TSX-V saw 3,324 price advancers against 1,856 declines and 124 unchanged.

During the prior 52 weeks, RX.VN has traded as high as $9.26 (December 29,2023) and low as $7.03 (July 06,2023). Moreover, the shares have boosted 6.38% in the last 12 months, while they have dipped -7.70% this year.

It announced a 0.04 dividend on February 07/24, with an February 28/24 ex-date and March 15/24 pay day.

Following today's trading, Biosyent Inc has a market capitalization of $98.80 million on a float of 11,610 shares outstanding. Its annual EPS is $0.53.

Biosyent Inc is a TSX Drug Specialty & Generic company headquartered in Mississauga, CAN.

Based on 1.00 analysts, Biosyent Inc gets an average recommendation of "Moderate Buy" according to Zacks. From those 1 analysts, 1 have buy ratings.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..

More from The Globe